{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:27:02Z","timestamp":1786998422069,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ygyno.2020.11.013","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T09:10:23Z","timestamp":1606122623000},"page":"418-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer"],"prefix":"10.1016","volume":"160","author":[{"given":"Anca","family":"Chelariu-Raicu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpa","family":"Nick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Gordinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Leuschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bavisotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziela Zibetti Dal","family":"Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Whisnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.ygyno.2020.11.013_bb0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_5-20","article-title":"Relapsed ovarian cancer: challenges and management strategies for a chronic disease","volume":"7","author":"Armstrong","year":"2002","journal-title":"Oncologist."},{"key":"10.1016\/j.ygyno.2020.11.013_bb0010","doi-asserted-by":"crossref","first-page":"413076","DOI":"10.1155\/2015\/413076","article-title":"Paclitaxel and its evolving role in the management of ovarian cancer","volume":"2015","author":"Kampan","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.013_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.3773","article-title":"Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial","volume":"5","author":"Falchook","year":"2019","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.013_bb0020","first-page":"1481","article-title":"Targeted chemotherapy for triple-negative breast cancers via LHRH receptor","volume":"25","author":"Fost","year":"2011","journal-title":"Oncol. Rep."},{"issue":"18","key":"10.1016\/j.ygyno.2020.11.013_bb0025","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1158\/1078-0432.CCR-10-1113","article-title":"Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists","volume":"16","author":"Liu","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ygyno.2020.11.013_bb0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.18632\/oncotarget.546","article-title":"Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]","volume":"3","author":"Szepeshazi","year":"2012","journal-title":"Oncotarget."},{"issue":"15","key":"10.1016\/j.ygyno.2020.11.013_bb0035","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-04-2464","article-title":"Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues","volume":"11","author":"Keller","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.ygyno.2020.11.013_bb0040","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1073\/pnas.88.10.4153","article-title":"Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells","volume":"88","author":"Szende","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.ygyno.2020.11.013_bb0045","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.3748\/wjg.v20.i20.6102","article-title":"Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives","volume":"20","author":"Hohla","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.013_bb0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3892\/ol.2017.6246","article-title":"(99m)Tc-LHRH in tumor receptor imaging","volume":"14","author":"Hao","year":"2017","journal-title":"Oncol. Lett."},{"issue":"13","key":"10.1016\/j.ygyno.2020.11.013_bb0055","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1158\/0008-5472.CAN-04-3816","article-title":"Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue","volume":"65","author":"Keller","year":"2005","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.ygyno.2020.11.013_bb0060","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.ejca.2005.06.018","article-title":"Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin\u2019s lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207","volume":"41","author":"Keller","year":"2005","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.013_bb0065","first-page":"1063","article-title":"Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines","volume":"17","author":"Westphalen","year":"2000","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.013_bb0070","first-page":"489","article-title":"Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer","volume":"12","author":"Srkalovic","year":"1998","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.11.013_bb0075","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00404-012-2335-1","article-title":"Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)","volume":"286","author":"Engel","year":"2012","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2020.11.013_bb0080","series-title":"Ep-100 Synergizes with Paclitaxel in Ovarian, Breast and Prostate Cancer Cell Lines AACR Conference, Chicago","author":"Leuschner","year":"2012"},{"issue":"8 Supplement","key":"10.1016\/j.ygyno.2020.11.013_bb0085","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1538-7445.AM2013-978","article-title":"Synergistic activity of Ep-100 and chemotherapies in cancer cell lines","volume":"73","author":"Leuschner","year":"2013","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.013_bb0090","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00280-014-2424-x","article-title":"Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors","volume":"73","author":"Curtis","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.11.013_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.013_bb0100","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2020.11.013_bb0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.ygyno.2020.11.013_bb0110","doi-asserted-by":"crossref","first-page":"12962","DOI":"10.1073\/pnas.0504274102","article-title":"Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide","volume":"102","author":"Dharap","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ygyno.2020.11.013_bb0115","article-title":"Targeted oncolytic peptide for treatment of ovarian cancers","volume":"3","author":"Leuschner","year":"2017","journal-title":"Int. J. Cancer Res. Molecular Mechanisms"},{"issue":"2","key":"10.1016\/j.ygyno.2020.11.013_bb0120","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/IGC.0000000000000044","article-title":"Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5)","volume":"24","author":"Emons","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2020.11.013_bb0125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2015.12.027","article-title":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","volume":"140","author":"Harter","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.11.013_bb0130","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/1535-7163.MCT-18-0770","article-title":"GnRH-R-targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition","volume":"18","author":"Ma","year":"2019","journal-title":"Mol. Cancer Ther."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582034124X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582034124X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:57:13Z","timestamp":1758772633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582034124X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S009082582034124X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}